Manufacturing showcase: a presentation on oligonucleotides
Currently, oligonucleotides are expensive to produce and their utility is limited by inefficiencies inherent in the manufacturing process and the finite quantity of some raw ingredients. Grand Challenge 3 at the Medicines Manufacturing Innovation – a collaboration between CPI, industry, academia and government – aims to revolutionise the oligonucleotide manufacturing process through the development of scalable, liquid phase API processes which will enable oligonucleotides to be manufactured on an industrial scale, more efficiently and at lower cost. By delivering this Grand Challenge, we will enable the industry to provide oligonucleotide therapeutics to much larger patient populations at affordable prices and in a sustainable way.
JOHN ARTHUR | Director | Medicines Manufacturing Innovation Centre